Ionis Pharmaceuticals Inc
IONS
Market Cap$5.98B
Close$
$-22.70
159.9% downside
Current Fair Value
159.9% downsideOvervalued by 159.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.98 Billion |
|---|---|
| Enterprise Value | $4.24 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.56 |
| Beta | 0.38 |
| Outstanding Shares | 145,958,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -15.15 |
|---|---|
| PEG | 67.76 |
| Price to Sales | 7.58 |
| Price to Book Ratio | 37.91 |
| Enterprise Value to Revenue | 5.22 |
| Enterprise Value to EBIT | -11.6 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 1.31 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...